Annual EBITDA
-$131.11 M
-$8.89 M-7.28%
December 31, 2023
Summary
- As of February 8, 2025, PRLD annual EBITDA is -$131.11 million, with the most recent change of -$8.89 million (-7.28%) on December 31, 2023.
- During the last 3 years, PRLD annual EBITDA has fallen by -$72.89 million (-125.19%).
- PRLD annual EBITDA is now -784.31% below its all-time high of -$14.83 million, reached on December 31, 2018.
Performance
PRLD EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$33.97 M
+$2.74 M+7.47%
September 30, 2024
Summary
- As of February 8, 2025, PRLD quarterly EBITDA is -$33.97 million, with the most recent change of +$2.74 million (+7.47%) on September 30, 2024.
- Over the past year, PRLD quarterly EBITDA has dropped by -$54.00 thousand (-0.16%).
- PRLD quarterly EBITDA is now -400.68% below its all-time high of -$6.79 million, reached on September 30, 2019.
Performance
PRLD Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$141.65 M
-$865.00 K-0.61%
September 30, 2024
Summary
- As of February 8, 2025, PRLD TTM EBITDA is -$141.65 million, with the most recent change of -$865.00 thousand (-0.61%) on September 30, 2024.
- Over the past year, PRLD TTM EBITDA has dropped by -$5.46 million (-4.01%).
- PRLD TTM EBITDA is now -1987.66% below its all-time high of -$6.79 million, reached on September 30, 2019.
Performance
PRLD TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PRLD EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -7.3% | -0.2% | -4.0% |
| 3 y3 years | -125.2% | -2.9% | -15.9% |
| 5 y5 years | -784.3% | -2.9% | -15.9% |
PRLD EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -16.2% | at low | -17.8% | +8.3% | -25.6% | at low |
| 5 y | 5-year | -372.9% | at low | -253.7% | +8.3% | -745.6% | at low |
| alltime | all time | -784.3% | at low | -400.7% | +8.3% | -1987.7% | at low |
Prelude Therapeutics Incorporated EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$33.97 M(-7.5%) | -$141.65 M(+0.6%) |
| Jun 2024 | - | -$36.71 M(+8.2%) | -$140.78 M(+3.4%) |
| Mar 2024 | - | -$33.92 M(-8.5%) | -$136.19 M(+3.9%) |
| Dec 2023 | -$131.11 M(+7.3%) | -$37.05 M(+11.9%) | -$131.11 M(+3.2%) |
| Sep 2023 | - | -$33.11 M(+3.1%) | -$127.08 M(+2.4%) |
| Jun 2023 | - | -$32.12 M(+11.4%) | -$124.05 M(+2.5%) |
| Mar 2023 | - | -$28.84 M(-12.7%) | -$121.07 M(-0.9%) |
| Dec 2022 | -$122.22 M(+8.3%) | -$33.02 M(+9.8%) | -$122.22 M(+0.2%) |
| Sep 2022 | - | -$30.07 M(+3.2%) | -$121.91 M(-0.4%) |
| Jun 2022 | - | -$29.14 M(-2.8%) | -$122.41 M(+1.2%) |
| Mar 2022 | - | -$29.98 M(-8.4%) | -$120.99 M(+7.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$112.82 M(+93.8%) | -$32.72 M(+7.0%) | -$112.82 M(+13.5%) |
| Sep 2021 | - | -$30.57 M(+10.3%) | -$99.41 M(+14.5%) |
| Jun 2021 | - | -$27.72 M(+27.1%) | -$86.84 M(+23.3%) |
| Mar 2021 | - | -$21.81 M(+12.9%) | -$70.42 M(+21.0%) |
| Dec 2020 | -$58.22 M(+110.0%) | -$19.31 M(+7.3%) | -$58.22 M(+19.1%) |
| Sep 2020 | - | -$18.00 M(+59.3%) | -$48.88 M(+29.8%) |
| Jun 2020 | - | -$11.30 M(+17.7%) | -$37.66 M(+42.9%) |
| Mar 2020 | - | -$9.61 M(-3.6%) | -$26.36 M(+57.3%) |
| Dec 2019 | -$27.73 M(+87.0%) | -$9.97 M(+46.9%) | -$16.75 M(+146.9%) |
| Sep 2019 | - | -$6.79 M | -$6.79 M |
| Dec 2018 | -$14.83 M | - | - |
FAQ
- What is Prelude Therapeutics Incorporated annual EBITDA?
- What is the all time high annual EBITDA for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated annual EBITDA year-on-year change?
- What is Prelude Therapeutics Incorporated quarterly EBITDA?
- What is the all time high quarterly EBITDA for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated quarterly EBITDA year-on-year change?
- What is Prelude Therapeutics Incorporated TTM EBITDA?
- What is the all time high TTM EBITDA for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated TTM EBITDA year-on-year change?
What is Prelude Therapeutics Incorporated annual EBITDA?
The current annual EBITDA of PRLD is -$131.11 M
What is the all time high annual EBITDA for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high annual EBITDA is -$14.83 M
What is Prelude Therapeutics Incorporated annual EBITDA year-on-year change?
Over the past year, PRLD annual EBITDA has changed by -$8.89 M (-7.28%)
What is Prelude Therapeutics Incorporated quarterly EBITDA?
The current quarterly EBITDA of PRLD is -$33.97 M
What is the all time high quarterly EBITDA for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high quarterly EBITDA is -$6.79 M
What is Prelude Therapeutics Incorporated quarterly EBITDA year-on-year change?
Over the past year, PRLD quarterly EBITDA has changed by -$54.00 K (-0.16%)
What is Prelude Therapeutics Incorporated TTM EBITDA?
The current TTM EBITDA of PRLD is -$141.65 M
What is the all time high TTM EBITDA for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high TTM EBITDA is -$6.79 M
What is Prelude Therapeutics Incorporated TTM EBITDA year-on-year change?
Over the past year, PRLD TTM EBITDA has changed by -$5.46 M (-4.01%)